1/13
10:58 am
bmea
Biomea Fusion (NASDAQ:BMEA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
Medium
Report
Biomea Fusion (NASDAQ:BMEA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $8.00 price target on the stock.
1/13
08:03 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $12.00 price target on the stock.
Neutral
Report
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $12.00 price target on the stock.
1/12
08:00 am
bmea
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Low
Report
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
12/17
07:16 am
bmea
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
07:00 am
bmea
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
06:11 am
bmea
Insider Spends US$99k Buying More Shares In Biomea Fusion [Yahoo! Finance]
Low
Report
Insider Spends US$99k Buying More Shares In Biomea Fusion [Yahoo! Finance]
12/9
06:35 pm
bmea
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
High
Report
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
12/5
07:00 am
bmea
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Low
Report
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/1
05:32 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/1
04:22 pm
bmea
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) [Yahoo! Finance]
Medium
Report
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) [Yahoo! Finance]
12/1
04:10 pm
bmea
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Medium
Report
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/1
04:05 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
11/24
07:00 am
bmea
Biomea Fusion to Participate at Upcoming Investor Conferences
Neutral
Report
Biomea Fusion to Participate at Upcoming Investor Conferences
11/10
04:52 pm
bmea
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at Citigroup Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at Citigroup Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.
11/10
07:00 am
bmea
Biomea Fusion to Participate at Jefferies London Healthcare Conference
Low
Report
Biomea Fusion to Participate at Jefferies London Healthcare Conference
11/5
08:45 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $12.00. They now have a "buy" rating on the stock.
11/5
07:00 am
bmea
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
Medium
Report
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
11/4
04:05 pm
bmea
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Medium
Report
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/30
08:00 am
bmea
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Low
Report
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
10/27
08:44 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Medium
Report
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
10/27
08:00 am
bmea
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Medium
Report
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
10/21
07:46 pm
bmea
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series [Yahoo! Finance]
Medium
Report
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series [Yahoo! Finance]
10/21
07:05 pm
bmea
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Medium
Report
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series